董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Keith Manchester | 男 | Independent Director | 57 | 50.39万美元 | 186.02 | 2026-07-29 |
| Mayukh Sukhatme | 男 | Director,Chief Investment Officer and President | 50 | 127.67万美元 | 2010.50 | 2026-07-29 |
| Frank Torti | 男 | President and Vant Chair | 47 | 12330.06万美元 | 753.04 | 2026-07-29 |
| Meghan FitzGerald | 女 | Independent Director | 55 | 50.99万美元 | 10.82 | 2026-07-29 |
| Matthew Gline | 男 | Chief Executive Officer and Director | 42 | 309.62万美元 | 1875.84 | 2026-07-29 |
| Daniel Gold | 男 | Independent Director | 58 | 51.14万美元 | 907.77 | 2026-07-29 |
| Melissa Epperly | 女 | Independent Director | 49 | 51.64万美元 | 22.56 | 2026-07-29 |
| James C. Momtazee | 男 | Independent Director | 54 | 49.74万美元 | 21.83 | 2026-07-29 |
| Ilan Oren | 男 | Chair of the Board and Independent Director | 42 | 54.84万美元 | 23.20 | 2026-07-29 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Mayukh Sukhatme | 男 | Director,Chief Investment Officer and President | 50 | 127.67万美元 | 2010.50 | 2026-07-29 |
| Matthew Gline | 男 | Chief Executive Officer and Director | 42 | 309.62万美元 | 1875.84 | 2026-07-29 |
| Eric Venker | 男 | President and Immunovant CEO | 39 | 2440.02万美元 | 863.41 | 2026-07-29 |
| Richard Pulik | 男 | Chief Financial Officer | 47 | 419.06万美元 | 169.99 | 2026-07-29 |
| Jennifer Humes | 女 | Chief Accounting Officer | 45 | 238.30万美元 | 未持股 | 2026-07-29 |
董事简历
中英对照 | 中文 | 英文- Keith Manchester
-
Keith Manchester，2014年11月起担任OnCore的董事。2005年起，在投资公司QVT Financial LP担任总经理和生命科学主管，专注于上市和私有生命科学公司。此前，2002-2004年，在生物科技公司- Applied Molecular Evolution, Inc.担任业务发展副总裁；2000-2002年担任业务发展总监。1999-2000年，在私募股权公司- Vestar Capital Partners担任合伙人。1997-1999年，在Goldman, Sachs & Co.的医疗集团担任投资银行家。他持有Harvard学院的学士学位和Harvard医学院的医学博士学位。
Keith Manchester has served as a director of Roivant since 2014. He serves as a Partner and the Head of Life Sciences at QVT Financial LP, an asset management company with offices in New York and New Delhi, where he has worked since 2005. He focuses on investments in both publicly traded and privately owned life science companies. Prior to joining QVT, Dr. Manchester was Vice President of Business Development from 2002 to 2004 and Director of Business Development from 2000 to 2002 at Applied Molecular Evolution, a biotechnology company. From 1999 to 2000, Dr. Manchester was an associate at Vestar Capital Partners, a private equity firm. From 1997 to 1999, Dr. Manchester was an investment banker in the healthcare group at Goldman Sachs. Dr. Manchester also serves on the board of directors of Kriya Therapeutics. He received his A.B. from Harvard College and his M.D. from Harvard Medical School. - Keith Manchester，2014年11月起担任OnCore的董事。2005年起，在投资公司QVT Financial LP担任总经理和生命科学主管，专注于上市和私有生命科学公司。此前，2002-2004年，在生物科技公司- Applied Molecular Evolution, Inc.担任业务发展副总裁；2000-2002年担任业务发展总监。1999-2000年，在私募股权公司- Vestar Capital Partners担任合伙人。1997-1999年，在Goldman, Sachs & Co.的医疗集团担任投资银行家。他持有Harvard学院的学士学位和Harvard医学院的医学博士学位。
- Keith Manchester has served as a director of Roivant since 2014. He serves as a Partner and the Head of Life Sciences at QVT Financial LP, an asset management company with offices in New York and New Delhi, where he has worked since 2005. He focuses on investments in both publicly traded and privately owned life science companies. Prior to joining QVT, Dr. Manchester was Vice President of Business Development from 2002 to 2004 and Director of Business Development from 2000 to 2002 at Applied Molecular Evolution, a biotechnology company. From 1999 to 2000, Dr. Manchester was an associate at Vestar Capital Partners, a private equity firm. From 1997 to 1999, Dr. Manchester was an investment banker in the healthcare group at Goldman Sachs. Dr. Manchester also serves on the board of directors of Kriya Therapeutics. He received his A.B. from Harvard College and his M.D. from Harvard Medical School.
- Mayukh Sukhatme
-
Mayukh Sukhatme，自2023年起担任Roivant的董事。Sukhatme博士还是Roivant Sciences Ltd.总裁兼首席投资官，自2021年1月起担任该职位，负责确定、尽职调查、制定Roivant新治疗方案的开发战略并进行交易。Sukhatme博士还告知Roivant对其现有生物制药子公司的看法，以便在整个Roivant投资组合中做出资本分配决策。Sukhatme博士于2015年加入Roivant，此前曾担任Roivant Pharma总裁和Roivant Sciences Ltd.首席商务官。Sukhatme博士为Roivant获得许可或获得的项目已经产生了所有11项Roivant Sciences Ltd.的阳性3期研究，并获得了8项FDA批准。从2000年到2015年，Sukhatme博士是几家大型机构投资公司的专注于医疗保健的分析师和投资组合经理，包括公开市场和风险投资公司。他的主要关注点是处于发展阶段的生物技术和制药公司，在那里他领导了对众多公司和药物化合物的尽职调查和投资决策，涉及范围广泛的治疗领域。Sukhatme博士在哈佛医学院获得医学博士学位，在麻省理工学院获得生物学学士学位和文学学士学位。
Mayukh Sukhatme has served as a director of Roivant since 2023. Dr. Sukhatme is also President and Chief Investment Officer, a position he has held since January 2021, and is responsible for identifying, performing diligence on, devising development strategies for and transacting on new therapeutic programs for Roivant. Dr. Sukhatme also informs Roivant's view of its existing biopharmaceutical subsidiary companies for capital allocation decisions across the Roivant portfolio. Dr. Sukhatme joined Roivant in 2015 and previously served as President of Roivant Pharma and as Chief Business Officer. Programs that Dr. Sukhatme has in licensed or acquired for Roivant have produced all 12 of positive Phase 3 studies and have garnered 8 FDA approvals. From 2000 to 2015, Dr. Sukhatme was a healthcare focused analyst and portfolio manager for several large institutional investment firms, including both public markets and venture capital firms. His principal focus was on development stage biotechnology and pharmaceutical companies, where he led diligence and investment decisions on numerous companies and pharmaceutical compounds across a wide variety of therapeutic areas. Dr. Sukhatme earned his M.D. from Harvard Medical School and his B.S. in Biology and B.S. in Literature from MIT. - Mayukh Sukhatme，自2023年起担任Roivant的董事。Sukhatme博士还是Roivant Sciences Ltd.总裁兼首席投资官，自2021年1月起担任该职位，负责确定、尽职调查、制定Roivant新治疗方案的开发战略并进行交易。Sukhatme博士还告知Roivant对其现有生物制药子公司的看法，以便在整个Roivant投资组合中做出资本分配决策。Sukhatme博士于2015年加入Roivant，此前曾担任Roivant Pharma总裁和Roivant Sciences Ltd.首席商务官。Sukhatme博士为Roivant获得许可或获得的项目已经产生了所有11项Roivant Sciences Ltd.的阳性3期研究，并获得了8项FDA批准。从2000年到2015年，Sukhatme博士是几家大型机构投资公司的专注于医疗保健的分析师和投资组合经理，包括公开市场和风险投资公司。他的主要关注点是处于发展阶段的生物技术和制药公司，在那里他领导了对众多公司和药物化合物的尽职调查和投资决策，涉及范围广泛的治疗领域。Sukhatme博士在哈佛医学院获得医学博士学位，在麻省理工学院获得生物学学士学位和文学学士学位。
- Mayukh Sukhatme has served as a director of Roivant since 2023. Dr. Sukhatme is also President and Chief Investment Officer, a position he has held since January 2021, and is responsible for identifying, performing diligence on, devising development strategies for and transacting on new therapeutic programs for Roivant. Dr. Sukhatme also informs Roivant's view of its existing biopharmaceutical subsidiary companies for capital allocation decisions across the Roivant portfolio. Dr. Sukhatme joined Roivant in 2015 and previously served as President of Roivant Pharma and as Chief Business Officer. Programs that Dr. Sukhatme has in licensed or acquired for Roivant have produced all 12 of positive Phase 3 studies and have garnered 8 FDA approvals. From 2000 to 2015, Dr. Sukhatme was a healthcare focused analyst and portfolio manager for several large institutional investment firms, including both public markets and venture capital firms. His principal focus was on development stage biotechnology and pharmaceutical companies, where he led diligence and investment decisions on numerous companies and pharmaceutical compounds across a wide variety of therapeutic areas. Dr. Sukhatme earned his M.D. from Harvard Medical School and his B.S. in Biology and B.S. in Literature from MIT.
- Frank Torti
-
Frank Torti自2014年7月起在董事会工作。他目前担任NEA的合伙人。在2007年加入NEA的时候，他在杜克大学临床和基因经济学中心（Duke University Center for Clinical & Genetic Economics）工作，参与跨国临床试验的临床试验研究与经济评价。他的经验也包括Wasatch Advisors的公共市场投资，消费者导向的医疗保健初创公司Revolution Health Group有限责任公司（Revolution Health Group LLC）的商务拓展。他目前是Galera Therapeutics 股份有限公司（Galera Therapeutics Inc）和Neotract股份有限公司（Neotract Inc）的董事会成员。他拥有North Carolina大学医学院硕士学位，哈佛商学院（Harvard Business School）工商管理硕士学位，North Carolina大学学士学位。
Frank Torti has served as President and Vant Chair since July 2025 and, prior to that role, as Vant Chair since January 2020. From August 2018 to December 2019, Dr. Torti served as Vant Investment Chair. In these roles, Dr. Torti has served as the chief executive officer, chair or a member of the board of directors of the biopharmaceutical companies in the Roivant family and is responsible for the operations and management of those companies. Dr. Torti has also served as Chair of Immunovant's board of directors since June 2019 and as its Executive Chair since August 2021, and also serves on the board of several of Roivant's private biopharmaceutical companies. Dr. Torti was the founding CEO and Chair of subsidiary Telavant from its inception in November 2022 until its sale to Roche for $7.25 billion in December 2023. Prior to joining Roivant, from August 2007 to August 2018 Dr. Torti served as a Partner of New Enterprise Associates, or NEA, specializing in investments in healthcare. Prior to joining NEA, Dr. Torti worked for the Duke University Center for Clinical & Genetic Economics from 2002 to 2005 in various capacities, where he was involved in clinical trials research and economic evaluations of multinational clinical trials. Dr. Torti previously served as chairman of the board of directors of Arbutus Biopharma from November 2018 until February 2025, as a director of Urovant Sciences Ltd., from August 2018 to December 2019, and as a director of Myovant Sciences Ltd., from November 2018 to December 2019. Dr. Torti earned an M.D. from the University of North Carolina School of Medicine, an M.B.A. from Harvard Business School and a B.A. from the University of North Carolina. - Frank Torti自2014年7月起在董事会工作。他目前担任NEA的合伙人。在2007年加入NEA的时候，他在杜克大学临床和基因经济学中心（Duke University Center for Clinical & Genetic Economics）工作，参与跨国临床试验的临床试验研究与经济评价。他的经验也包括Wasatch Advisors的公共市场投资，消费者导向的医疗保健初创公司Revolution Health Group有限责任公司（Revolution Health Group LLC）的商务拓展。他目前是Galera Therapeutics 股份有限公司（Galera Therapeutics Inc）和Neotract股份有限公司（Neotract Inc）的董事会成员。他拥有North Carolina大学医学院硕士学位，哈佛商学院（Harvard Business School）工商管理硕士学位，North Carolina大学学士学位。
- Frank Torti has served as President and Vant Chair since July 2025 and, prior to that role, as Vant Chair since January 2020. From August 2018 to December 2019, Dr. Torti served as Vant Investment Chair. In these roles, Dr. Torti has served as the chief executive officer, chair or a member of the board of directors of the biopharmaceutical companies in the Roivant family and is responsible for the operations and management of those companies. Dr. Torti has also served as Chair of Immunovant's board of directors since June 2019 and as its Executive Chair since August 2021, and also serves on the board of several of Roivant's private biopharmaceutical companies. Dr. Torti was the founding CEO and Chair of subsidiary Telavant from its inception in November 2022 until its sale to Roche for $7.25 billion in December 2023. Prior to joining Roivant, from August 2007 to August 2018 Dr. Torti served as a Partner of New Enterprise Associates, or NEA, specializing in investments in healthcare. Prior to joining NEA, Dr. Torti worked for the Duke University Center for Clinical & Genetic Economics from 2002 to 2005 in various capacities, where he was involved in clinical trials research and economic evaluations of multinational clinical trials. Dr. Torti previously served as chairman of the board of directors of Arbutus Biopharma from November 2018 until February 2025, as a director of Urovant Sciences Ltd., from August 2018 to December 2019, and as a director of Myovant Sciences Ltd., from November 2018 to December 2019. Dr. Torti earned an M.D. from the University of North Carolina School of Medicine, an M.B.A. from Harvard Business School and a B.A. from the University of North Carolina.
- Meghan FitzGerald
-
Meghan FitzGerald，自2016年3月起担任Concert Pharmaceuticals, Inc.的董事会成员。自2016年12月起，她担任L1 Health LLC（一家专注于医疗保健投资的投资基金）的管理合伙人。从2015年5月到2016年10月，她担任Cardinal Health（一家医疗保健服务和产品公司）的战略和政策执行副总裁。从2010年10月到2015年5月，她担任Cardinal Health Specialty Solutions的总裁。自2017年7月起，她担任Arix Bioscience plc（上市生物技术公司）的董事会成员。她还担任一些私人生物技术公司的董事会成员。她在纽约医学院（New York Medical College）获得公共卫生博士学位，专注于卫生政策。她还获得了哥伦比亚大学（Columbia University）的公共卫生硕士学位和费尔菲尔德大学（Fairfield University）的护理学士学位。
Meghan FitzGerald has served as a director of Roivant since 2023. Ms. FitzGerald is a global healthcare strategist, investor, academic and author. She has worked across the healthcare industry from front line patient care through the Fortune 500, and also serves as an Adjunct Professor of Health Policy at Columbia University. Ms. FitzGerald is a private equity investor where she serves as a senior advisor to several firms, including Goldman Sachs and Towerbrook. Ms. FitzGerald served from December 2016 to January 2020 as the Chief Executive Officer and Managing Partner at Letter One's inaugural health vehicle, L1 Health. Prior to that, she spent twenty years working for many prominent healthcare companies, including Cardinal Health, Medco Health Systems, Pfizer, Merck and Sanofi Synthelabo. Currently, Ms. FitzGerald also serves on the boards of directors of Tenet Healthcare, 4G Clinical, ABB Optical Group, Rayus Radiology and Quanta Dialysis Technologies and is a founder of K2HealthVentures, a life science investment fund. She previously served as a director of Thimblepoint Acquisition Corp., from February to December 2021. Ms. FitzGerald received a Doctor of Public Health from New York Medical College, a Master of Public Health from Columbia University and a BSN in Nursing from Fairfield University. - Meghan FitzGerald，自2016年3月起担任Concert Pharmaceuticals, Inc.的董事会成员。自2016年12月起，她担任L1 Health LLC（一家专注于医疗保健投资的投资基金）的管理合伙人。从2015年5月到2016年10月，她担任Cardinal Health（一家医疗保健服务和产品公司）的战略和政策执行副总裁。从2010年10月到2015年5月，她担任Cardinal Health Specialty Solutions的总裁。自2017年7月起，她担任Arix Bioscience plc（上市生物技术公司）的董事会成员。她还担任一些私人生物技术公司的董事会成员。她在纽约医学院（New York Medical College）获得公共卫生博士学位，专注于卫生政策。她还获得了哥伦比亚大学（Columbia University）的公共卫生硕士学位和费尔菲尔德大学（Fairfield University）的护理学士学位。
- Meghan FitzGerald has served as a director of Roivant since 2023. Ms. FitzGerald is a global healthcare strategist, investor, academic and author. She has worked across the healthcare industry from front line patient care through the Fortune 500, and also serves as an Adjunct Professor of Health Policy at Columbia University. Ms. FitzGerald is a private equity investor where she serves as a senior advisor to several firms, including Goldman Sachs and Towerbrook. Ms. FitzGerald served from December 2016 to January 2020 as the Chief Executive Officer and Managing Partner at Letter One's inaugural health vehicle, L1 Health. Prior to that, she spent twenty years working for many prominent healthcare companies, including Cardinal Health, Medco Health Systems, Pfizer, Merck and Sanofi Synthelabo. Currently, Ms. FitzGerald also serves on the boards of directors of Tenet Healthcare, 4G Clinical, ABB Optical Group, Rayus Radiology and Quanta Dialysis Technologies and is a founder of K2HealthVentures, a life science investment fund. She previously served as a director of Thimblepoint Acquisition Corp., from February to December 2021. Ms. FitzGerald received a Doctor of Public Health from New York Medical College, a Master of Public Health from Columbia University and a BSN in Nursing from Fairfield University.
- Matthew Gline
-
Matthew Gline自2018年7月以来一直担任我们的董事会成员。自2017年9月以来，Gline先生一直担任Roivant Sciences，Inc.（RSI）的首席财务官。Gline先生此前自2016年3月起担任RSI&；8217；S的财务和业务运营高级副总裁，。2014年4月至2016年3月，他是高盛（Goldman Sachs&Co.LLC）固定收益数字结构Vice President，专注于技术和数据战略。Gline从2012年5月到2014年3月担任FourThree（一家风险分析技术和咨询公司）联合创始人。从2008年到2012年，他担任巴克莱资本公司（Barclays Capital Inc.）企业风险管理顾问Vice President，为企业客户提供融资和风险管理方面的资本市场准入分析。Gline先生在哈佛大学（Harvard University）获得物理学学士学位。
Matthew Gline has served as Chief Executive Officer since January 2021 and as a director of Roivant since September 2021. As CEO, Mr. Gline plays a key role in setting the strategy for Roivant along with the rest of the Board of Directors and executing on that strategy with management team, including making capital allocation decisions across the Roivant portfolio. Mr. Gline joined Roivant in March 2016 and previously served as Chief Financial Officer, from September 2017 through his appointment as Chief Executive Officer, and as Senior VP, Finance and Business Operations. Prior to joining Roivant, Mr. Gline was a Vice President at Goldman Sachs, Fixed Income Digital Structuring, from 2014 to 2016, and co founded Fourthree, a risk analytics technology and consulting company, from 2012 to 2014. Mr. Gline also serves on the board of directors of Datavant, the world's largest health data ecosystem, and Arbutus Biopharma Corporation. Mr. Gline earned his A.B. in Physics from Harvard College. - Matthew Gline自2018年7月以来一直担任我们的董事会成员。自2017年9月以来，Gline先生一直担任Roivant Sciences，Inc.（RSI）的首席财务官。Gline先生此前自2016年3月起担任RSI&；8217；S的财务和业务运营高级副总裁，。2014年4月至2016年3月，他是高盛（Goldman Sachs&Co.LLC）固定收益数字结构Vice President，专注于技术和数据战略。Gline从2012年5月到2014年3月担任FourThree（一家风险分析技术和咨询公司）联合创始人。从2008年到2012年，他担任巴克莱资本公司（Barclays Capital Inc.）企业风险管理顾问Vice President，为企业客户提供融资和风险管理方面的资本市场准入分析。Gline先生在哈佛大学（Harvard University）获得物理学学士学位。
- Matthew Gline has served as Chief Executive Officer since January 2021 and as a director of Roivant since September 2021. As CEO, Mr. Gline plays a key role in setting the strategy for Roivant along with the rest of the Board of Directors and executing on that strategy with management team, including making capital allocation decisions across the Roivant portfolio. Mr. Gline joined Roivant in March 2016 and previously served as Chief Financial Officer, from September 2017 through his appointment as Chief Executive Officer, and as Senior VP, Finance and Business Operations. Prior to joining Roivant, Mr. Gline was a Vice President at Goldman Sachs, Fixed Income Digital Structuring, from 2014 to 2016, and co founded Fourthree, a risk analytics technology and consulting company, from 2012 to 2014. Mr. Gline also serves on the board of directors of Datavant, the world's largest health data ecosystem, and Arbutus Biopharma Corporation. Mr. Gline earned his A.B. in Physics from Harvard College.
- Daniel Gold
-
Daniel Gold是QVT Financial LP和QVT Family Office Together，“；QVT”；的Founder兼首席执行官，这两家公司都是另类投资管理公司。创立QVT公司之前，他曾担任Deutsche Bank公司（跨国投资银行和金融服务公司）的董事总经理，在那里他曾管理自营交易集团，该集团于2003年通过分拆成为QVT公司。在Deutsche Bank之前，他在Daiwa Securities和Bear Stearns工作。戈尔德先生毕业于哈佛大学，获得物理学学士学位。Gold先生目前还担任Okeanis Eco Tankers Corp.和Awilco Drilling plc的董事会成员，此外还有各种私人公司，包括Roivant Sciences Ltd.和GridPoint Inc.。
Daniel Gold has served as a director of Roivant since 2020. Mr. Gold is the Founder and CEO of QVT Financial LP, an asset management company with offices in New York and New Delhi. QVT, through its managed and affiliated multi strategy funds, is an experienced global investor in multiple industries, including biotech, financial and the shipping and offshore industries. Mr. Gold also serves on the boards of directors of Okeanis Eco Tankers Corp., Awilco Drilling PLC and Integrated Wind Solutions ASA in addition to various private companies. Mr. Gold holds an A.B. in Physics from Harvard College. - Daniel Gold是QVT Financial LP和QVT Family Office Together，“；QVT”；的Founder兼首席执行官，这两家公司都是另类投资管理公司。创立QVT公司之前，他曾担任Deutsche Bank公司（跨国投资银行和金融服务公司）的董事总经理，在那里他曾管理自营交易集团，该集团于2003年通过分拆成为QVT公司。在Deutsche Bank之前，他在Daiwa Securities和Bear Stearns工作。戈尔德先生毕业于哈佛大学，获得物理学学士学位。Gold先生目前还担任Okeanis Eco Tankers Corp.和Awilco Drilling plc的董事会成员，此外还有各种私人公司，包括Roivant Sciences Ltd.和GridPoint Inc.。
- Daniel Gold has served as a director of Roivant since 2020. Mr. Gold is the Founder and CEO of QVT Financial LP, an asset management company with offices in New York and New Delhi. QVT, through its managed and affiliated multi strategy funds, is an experienced global investor in multiple industries, including biotech, financial and the shipping and offshore industries. Mr. Gold also serves on the boards of directors of Okeanis Eco Tankers Corp., Awilco Drilling PLC and Integrated Wind Solutions ASA in addition to various private companies. Mr. Gold holds an A.B. in Physics from Harvard College.
- Melissa Epperly
-
Melissa Epperly，自2022年6月起担任Roivant董事。Epperly女士自2019年9月起担任临床阶段癌症公司Zentalis Pharmaceuticals, Inc.的首席财务官。从2018年6月至2019年8月，埃珀利女士担任PsiOxus Therapeutics Ltd.的首席财务官，该公司是一家临床阶段的基因治疗癌症公司，她领导该公司的财务运营。在加入PsiOxus之前，Epperly女士曾于2015年10月至2018年6月在处于商业化阶段的肿瘤公司R-Pharm US担任首席财务官兼业务发展主管，负责公司的财务运营和业务发展。Epperly女士于2012年8月至2015年9月担任专注于信贷的对冲基金Anchorage Capital Group的董事。在此之前，埃珀利女士曾在纽约和伦敦的高盛集团担任股票研究副总裁，在贝恩公司担任管理顾问，在摩根士丹利担任医疗保健投资银行家。Epperly女士目前是Kinnate生物制药公司和Nautilus生物技术公司的董事会成员。埃珀利拥有弗吉尼亚大学生物化学和经济学学士学位和哈佛商学院工商管理硕士学位。
Melissa Epperly has served as a director of Roivant since 2022. Since June 2025, Ms. Epperly has served as Chief Financial Officer at Tenpoint Therapeutics, Ltd., a global commercial ready biotechnology company. Previously, Ms. Epperly served as Chief Financial Officer at Zentalis Pharmaceuticals, Inc., a clinical stage cancer company, from September 2019 to April 2024. Prior to that, she served as Chief Financial Officer of PsiOxus Therapeutics Ltd., a clinical stage gene therapy cancer company, from June 2018 to August 2019, and as Chief Financial Officer and Head of Business Development at R Pharm US, a commercial stage oncology company, from October 2015 to June 2018. Ms. Epperly also served as a Director at Anchorage Capital Group, a credit focused hedge fund from August 2012 to September 2015. Previously, Ms. Epperly was a Vice President at Goldman Sachs in equity research in New York and London, a management consultant with Bain & Company and a healthcare investment banker at Morgan Stanley. Ms. Epperly also serves on the board of directors of Nautilus Biotechnology. Ms. Epperly holds a B.A. in Biochemistry and Economics from the University of Virginia and an M.B.A from Harvard Business School. - Melissa Epperly，自2022年6月起担任Roivant董事。Epperly女士自2019年9月起担任临床阶段癌症公司Zentalis Pharmaceuticals, Inc.的首席财务官。从2018年6月至2019年8月，埃珀利女士担任PsiOxus Therapeutics Ltd.的首席财务官，该公司是一家临床阶段的基因治疗癌症公司，她领导该公司的财务运营。在加入PsiOxus之前，Epperly女士曾于2015年10月至2018年6月在处于商业化阶段的肿瘤公司R-Pharm US担任首席财务官兼业务发展主管，负责公司的财务运营和业务发展。Epperly女士于2012年8月至2015年9月担任专注于信贷的对冲基金Anchorage Capital Group的董事。在此之前，埃珀利女士曾在纽约和伦敦的高盛集团担任股票研究副总裁，在贝恩公司担任管理顾问，在摩根士丹利担任医疗保健投资银行家。Epperly女士目前是Kinnate生物制药公司和Nautilus生物技术公司的董事会成员。埃珀利拥有弗吉尼亚大学生物化学和经济学学士学位和哈佛商学院工商管理硕士学位。
- Melissa Epperly has served as a director of Roivant since 2022. Since June 2025, Ms. Epperly has served as Chief Financial Officer at Tenpoint Therapeutics, Ltd., a global commercial ready biotechnology company. Previously, Ms. Epperly served as Chief Financial Officer at Zentalis Pharmaceuticals, Inc., a clinical stage cancer company, from September 2019 to April 2024. Prior to that, she served as Chief Financial Officer of PsiOxus Therapeutics Ltd., a clinical stage gene therapy cancer company, from June 2018 to August 2019, and as Chief Financial Officer and Head of Business Development at R Pharm US, a commercial stage oncology company, from October 2015 to June 2018. Ms. Epperly also served as a Director at Anchorage Capital Group, a credit focused hedge fund from August 2012 to September 2015. Previously, Ms. Epperly was a Vice President at Goldman Sachs in equity research in New York and London, a management consultant with Bain & Company and a healthcare investment banker at Morgan Stanley. Ms. Epperly also serves on the board of directors of Nautilus Biotechnology. Ms. Epperly holds a B.A. in Biochemistry and Economics from the University of Virginia and an M.B.A from Harvard Business School.
- James C. Momtazee
-
James C. Momtazee，自2021年9月起担任Roivant董事。Momtazee先生是专门的医疗保健投资公司Patient Square Capital的管理合伙人。Momtazee先生拥有超过28年的投资和收购经验，其中绝大多数专注于医疗保健行业。在创立Patient Square之前，他自1996年起在KKR公司（“KKR”）担任多个职位。2001年，他帮助组建了KKR的医疗行业集团，并管理该团队超过10年。Momtazee先生目前还担任Enavate Sciences、BridgeBio Pharma、Apollo Therapeutics、Kriya Therapeutics、Alladapt Immunotherapeutics、Elevage Medical Technologies和医疗器械制造商协会的董事会成员，并曾担任其他多家医疗保健公司的董事会成员，包括PRA健康科学公司（首席独立董事）、Envision Healthcare、Heartland Dental、Ajax Health、Global Medical Response、BrightSpring Health Services、Covenant Surgical Partners、Entellus医疗公司、EchoNous、Spirox，Inc.、Arbor Pharmaceuticals、Lake Region Medical、HCA健康护理、爵士制药和Alliance Imaging。Momtazee先生于2020年10月至2021年10月担任Montes Archimedes Acquisition Corp的董事长、首席执行官兼总裁。他在斯坦福大学获得了A.B.学位，在斯坦福大学商学院获得了MBA学位。
James C. Momtazee has served as a director of Roivant since 2021. Mr. Momtazee is the Managing Partner of Patient Square Capital, LP, a dedicated health care investing firm. Mr. Momtazee has over 30 years of investment and acquisition experience, the vast majority of which was focused on the health care sector. Prior to founding Patient Square, he held various positions at KKR & Co., Inc. since 1996. He helped form KKR's health care industry group in 2001 and ran that team for over 10 years. Mr. Momtazee also serves on the boards of directors of EMT Holdings, Apollo Therapeutics, Kriya Therapeutics, Enavate Sciences, Elevage Medical Technologies, Syneos Health, GondolaBio, Hanger, BridgeBio Pharma, Osanni Bio and the Medical Device Manufacturers Association. Mr. Momtazee was Chairman, CEO and President of Montes Archimedes Acquisition Corp. from October 2020 until October 2021. He received an A.B. from Stanford University and an M.B.A. from the Stanford Graduate School of Business. - James C. Momtazee，自2021年9月起担任Roivant董事。Momtazee先生是专门的医疗保健投资公司Patient Square Capital的管理合伙人。Momtazee先生拥有超过28年的投资和收购经验，其中绝大多数专注于医疗保健行业。在创立Patient Square之前，他自1996年起在KKR公司（“KKR”）担任多个职位。2001年，他帮助组建了KKR的医疗行业集团，并管理该团队超过10年。Momtazee先生目前还担任Enavate Sciences、BridgeBio Pharma、Apollo Therapeutics、Kriya Therapeutics、Alladapt Immunotherapeutics、Elevage Medical Technologies和医疗器械制造商协会的董事会成员，并曾担任其他多家医疗保健公司的董事会成员，包括PRA健康科学公司（首席独立董事）、Envision Healthcare、Heartland Dental、Ajax Health、Global Medical Response、BrightSpring Health Services、Covenant Surgical Partners、Entellus医疗公司、EchoNous、Spirox，Inc.、Arbor Pharmaceuticals、Lake Region Medical、HCA健康护理、爵士制药和Alliance Imaging。Momtazee先生于2020年10月至2021年10月担任Montes Archimedes Acquisition Corp的董事长、首席执行官兼总裁。他在斯坦福大学获得了A.B.学位，在斯坦福大学商学院获得了MBA学位。
- James C. Momtazee has served as a director of Roivant since 2021. Mr. Momtazee is the Managing Partner of Patient Square Capital, LP, a dedicated health care investing firm. Mr. Momtazee has over 30 years of investment and acquisition experience, the vast majority of which was focused on the health care sector. Prior to founding Patient Square, he held various positions at KKR & Co., Inc. since 1996. He helped form KKR's health care industry group in 2001 and ran that team for over 10 years. Mr. Momtazee also serves on the boards of directors of EMT Holdings, Apollo Therapeutics, Kriya Therapeutics, Enavate Sciences, Elevage Medical Technologies, Syneos Health, GondolaBio, Hanger, BridgeBio Pharma, Osanni Bio and the Medical Device Manufacturers Association. Mr. Momtazee was Chairman, CEO and President of Montes Archimedes Acquisition Corp. from October 2020 until October 2021. He received an A.B. from Stanford University and an M.B.A. from the Stanford Graduate School of Business.
- Ilan Oren
-
Ilan Oren自2023年2月起担任Roivant董事会主席，自2014年起担任Roivant董事。奥伦先生自2019年11月起担任以色列私营制药集团Dexcel Pharma的联席首席执行官。在担任联席首席执行官之前，奥伦先生曾担任集团副总裁，领导公司和业务发展活动，包括组建战略企业、产品合作伙伴关系、产品组合选择、产品收购、战略投资和并购。Oren先生目前是Clexio Biosciences和Kriya Therapeutics的董事会成员，曾担任Sio Gene Therapies和Cynapsus Therapeutics的董事会成员。他拥有哈佛大学经济学学士学位。
Ilan Oren is the Chair of Roivant's Board of Directors, a position he has held since 2023, having served as a director of Roivant since 2014. He has served as Co Chief Executive Officer of Dexcel Pharma, part of a privately owned Israeli group of pharmaceutical companies, since November 2019. Prior to serving as Co CEO, Mr. Oren served as Vice President for the group and led corporate and business development activities, including formation of strategic ventures, product partnerships, product portfolio selection, product acquisitions, strategic investments and mergers and acquisitions. Mr. Oren is the Chairman of the Board of Syremis Therapeutics and also serves on the boards of directors of Clexio Biosciences and Kriya Therapeutics and has previously served on the boards of directors of Sio Gene Therapies and Cynapsus Therapeutics. He holds an A.B. in Economics from Harvard College. - Ilan Oren自2023年2月起担任Roivant董事会主席，自2014年起担任Roivant董事。奥伦先生自2019年11月起担任以色列私营制药集团Dexcel Pharma的联席首席执行官。在担任联席首席执行官之前，奥伦先生曾担任集团副总裁，领导公司和业务发展活动，包括组建战略企业、产品合作伙伴关系、产品组合选择、产品收购、战略投资和并购。Oren先生目前是Clexio Biosciences和Kriya Therapeutics的董事会成员，曾担任Sio Gene Therapies和Cynapsus Therapeutics的董事会成员。他拥有哈佛大学经济学学士学位。
- Ilan Oren is the Chair of Roivant's Board of Directors, a position he has held since 2023, having served as a director of Roivant since 2014. He has served as Co Chief Executive Officer of Dexcel Pharma, part of a privately owned Israeli group of pharmaceutical companies, since November 2019. Prior to serving as Co CEO, Mr. Oren served as Vice President for the group and led corporate and business development activities, including formation of strategic ventures, product partnerships, product portfolio selection, product acquisitions, strategic investments and mergers and acquisitions. Mr. Oren is the Chairman of the Board of Syremis Therapeutics and also serves on the boards of directors of Clexio Biosciences and Kriya Therapeutics and has previously served on the boards of directors of Sio Gene Therapies and Cynapsus Therapeutics. He holds an A.B. in Economics from Harvard College.
高管简历
中英对照 | 中文 | 英文- Mayukh Sukhatme
Mayukh Sukhatme，自2023年起担任Roivant的董事。Sukhatme博士还是Roivant Sciences Ltd.总裁兼首席投资官，自2021年1月起担任该职位，负责确定、尽职调查、制定Roivant新治疗方案的开发战略并进行交易。Sukhatme博士还告知Roivant对其现有生物制药子公司的看法，以便在整个Roivant投资组合中做出资本分配决策。Sukhatme博士于2015年加入Roivant，此前曾担任Roivant Pharma总裁和Roivant Sciences Ltd.首席商务官。Sukhatme博士为Roivant获得许可或获得的项目已经产生了所有11项Roivant Sciences Ltd.的阳性3期研究，并获得了8项FDA批准。从2000年到2015年，Sukhatme博士是几家大型机构投资公司的专注于医疗保健的分析师和投资组合经理，包括公开市场和风险投资公司。他的主要关注点是处于发展阶段的生物技术和制药公司，在那里他领导了对众多公司和药物化合物的尽职调查和投资决策，涉及范围广泛的治疗领域。Sukhatme博士在哈佛医学院获得医学博士学位，在麻省理工学院获得生物学学士学位和文学学士学位。
Mayukh Sukhatme has served as a director of Roivant since 2023. Dr. Sukhatme is also President and Chief Investment Officer, a position he has held since January 2021, and is responsible for identifying, performing diligence on, devising development strategies for and transacting on new therapeutic programs for Roivant. Dr. Sukhatme also informs Roivant's view of its existing biopharmaceutical subsidiary companies for capital allocation decisions across the Roivant portfolio. Dr. Sukhatme joined Roivant in 2015 and previously served as President of Roivant Pharma and as Chief Business Officer. Programs that Dr. Sukhatme has in licensed or acquired for Roivant have produced all 12 of positive Phase 3 studies and have garnered 8 FDA approvals. From 2000 to 2015, Dr. Sukhatme was a healthcare focused analyst and portfolio manager for several large institutional investment firms, including both public markets and venture capital firms. His principal focus was on development stage biotechnology and pharmaceutical companies, where he led diligence and investment decisions on numerous companies and pharmaceutical compounds across a wide variety of therapeutic areas. Dr. Sukhatme earned his M.D. from Harvard Medical School and his B.S. in Biology and B.S. in Literature from MIT.- Mayukh Sukhatme，自2023年起担任Roivant的董事。Sukhatme博士还是Roivant Sciences Ltd.总裁兼首席投资官，自2021年1月起担任该职位，负责确定、尽职调查、制定Roivant新治疗方案的开发战略并进行交易。Sukhatme博士还告知Roivant对其现有生物制药子公司的看法，以便在整个Roivant投资组合中做出资本分配决策。Sukhatme博士于2015年加入Roivant，此前曾担任Roivant Pharma总裁和Roivant Sciences Ltd.首席商务官。Sukhatme博士为Roivant获得许可或获得的项目已经产生了所有11项Roivant Sciences Ltd.的阳性3期研究，并获得了8项FDA批准。从2000年到2015年，Sukhatme博士是几家大型机构投资公司的专注于医疗保健的分析师和投资组合经理，包括公开市场和风险投资公司。他的主要关注点是处于发展阶段的生物技术和制药公司，在那里他领导了对众多公司和药物化合物的尽职调查和投资决策，涉及范围广泛的治疗领域。Sukhatme博士在哈佛医学院获得医学博士学位，在麻省理工学院获得生物学学士学位和文学学士学位。
- Mayukh Sukhatme has served as a director of Roivant since 2023. Dr. Sukhatme is also President and Chief Investment Officer, a position he has held since January 2021, and is responsible for identifying, performing diligence on, devising development strategies for and transacting on new therapeutic programs for Roivant. Dr. Sukhatme also informs Roivant's view of its existing biopharmaceutical subsidiary companies for capital allocation decisions across the Roivant portfolio. Dr. Sukhatme joined Roivant in 2015 and previously served as President of Roivant Pharma and as Chief Business Officer. Programs that Dr. Sukhatme has in licensed or acquired for Roivant have produced all 12 of positive Phase 3 studies and have garnered 8 FDA approvals. From 2000 to 2015, Dr. Sukhatme was a healthcare focused analyst and portfolio manager for several large institutional investment firms, including both public markets and venture capital firms. His principal focus was on development stage biotechnology and pharmaceutical companies, where he led diligence and investment decisions on numerous companies and pharmaceutical compounds across a wide variety of therapeutic areas. Dr. Sukhatme earned his M.D. from Harvard Medical School and his B.S. in Biology and B.S. in Literature from MIT.
- Matthew Gline
Matthew Gline自2018年7月以来一直担任我们的董事会成员。自2017年9月以来，Gline先生一直担任Roivant Sciences，Inc.（RSI）的首席财务官。Gline先生此前自2016年3月起担任RSI&；8217；S的财务和业务运营高级副总裁，。2014年4月至2016年3月，他是高盛（Goldman Sachs&Co.LLC）固定收益数字结构Vice President，专注于技术和数据战略。Gline从2012年5月到2014年3月担任FourThree（一家风险分析技术和咨询公司）联合创始人。从2008年到2012年，他担任巴克莱资本公司（Barclays Capital Inc.）企业风险管理顾问Vice President，为企业客户提供融资和风险管理方面的资本市场准入分析。Gline先生在哈佛大学（Harvard University）获得物理学学士学位。
Matthew Gline has served as Chief Executive Officer since January 2021 and as a director of Roivant since September 2021. As CEO, Mr. Gline plays a key role in setting the strategy for Roivant along with the rest of the Board of Directors and executing on that strategy with management team, including making capital allocation decisions across the Roivant portfolio. Mr. Gline joined Roivant in March 2016 and previously served as Chief Financial Officer, from September 2017 through his appointment as Chief Executive Officer, and as Senior VP, Finance and Business Operations. Prior to joining Roivant, Mr. Gline was a Vice President at Goldman Sachs, Fixed Income Digital Structuring, from 2014 to 2016, and co founded Fourthree, a risk analytics technology and consulting company, from 2012 to 2014. Mr. Gline also serves on the board of directors of Datavant, the world's largest health data ecosystem, and Arbutus Biopharma Corporation. Mr. Gline earned his A.B. in Physics from Harvard College.- Matthew Gline自2018年7月以来一直担任我们的董事会成员。自2017年9月以来，Gline先生一直担任Roivant Sciences，Inc.（RSI）的首席财务官。Gline先生此前自2016年3月起担任RSI&；8217；S的财务和业务运营高级副总裁，。2014年4月至2016年3月，他是高盛（Goldman Sachs&Co.LLC）固定收益数字结构Vice President，专注于技术和数据战略。Gline从2012年5月到2014年3月担任FourThree（一家风险分析技术和咨询公司）联合创始人。从2008年到2012年，他担任巴克莱资本公司（Barclays Capital Inc.）企业风险管理顾问Vice President，为企业客户提供融资和风险管理方面的资本市场准入分析。Gline先生在哈佛大学（Harvard University）获得物理学学士学位。
- Matthew Gline has served as Chief Executive Officer since January 2021 and as a director of Roivant since September 2021. As CEO, Mr. Gline plays a key role in setting the strategy for Roivant along with the rest of the Board of Directors and executing on that strategy with management team, including making capital allocation decisions across the Roivant portfolio. Mr. Gline joined Roivant in March 2016 and previously served as Chief Financial Officer, from September 2017 through his appointment as Chief Executive Officer, and as Senior VP, Finance and Business Operations. Prior to joining Roivant, Mr. Gline was a Vice President at Goldman Sachs, Fixed Income Digital Structuring, from 2014 to 2016, and co founded Fourthree, a risk analytics technology and consulting company, from 2012 to 2014. Mr. Gline also serves on the board of directors of Datavant, the world's largest health data ecosystem, and Arbutus Biopharma Corporation. Mr. Gline earned his A.B. in Physics from Harvard College.
- Eric Venker
Eric Venker自2020年2月起担任董事会成员。Venker博士自2018年11月起担任RSI首席运营官。2017年10月至2018年10月，Venker博士担任RSI&8217；s首席执行官的办公室主任，并于2014年至2015年担任RSI的分析师。2015年至2017年，Venker博士是纽约长老会医院/哥伦比亚大学医学中心的医生，在那里他接受了内科培训，并担任家庭成员质量委员会主席，领导提高效率的运营计划。Venker从2011年到2015年担任Yale-New Haven Hospital临床药剂师。Venker博士还担任Arbutus Biopharma Corporation公司和Immunovant，Inc.公司的董事，这两家公司都是生物制药公司，Venker博士获得了医药博士学位。St.Louis College of Pharmacy的医学博士学位和Yale School of Medicine的医学博士学位。
Eric Venker has served as Immunovant, Inc.'s Chief Executive Officer since April 2025 and as a member of Immunovant, Inc.'s Board since February 2020. Dr. Venker continues to serve with RSI as President and Immunovant CEO, having previously served as President and Chief Operating Officer of RSI since January 2021, and prior to that, as Chief Operating Officer of RSI since November 2018. Previously, from October 2017 to October 2018, he was Chief of Staff to RSI's Chief Executive Officer, and from 2014 to 2015, an Analyst at RSI. From 2015 to 2017, Dr. Venker was a physician at New York Presbyterian Hospital/Columbia University Medical Center, where he trained in internal medicine. From 2011 to 2015, Dr. Venker was a Clinical Pharmacist at Yale New Haven Hospital. Dr. Venker presently serves on the boards of directors of several of Roivant's private biopharmaceutical companies. Dr. Venker previously served on the boards of Sio Gene Therapies, Inc. and Arbutus Biopharma Corporation. He received his Pharm.D. from St. Louis College of Pharmacy and his M.D. from Yale School of Medicine.- Eric Venker自2020年2月起担任董事会成员。Venker博士自2018年11月起担任RSI首席运营官。2017年10月至2018年10月，Venker博士担任RSI&8217；s首席执行官的办公室主任，并于2014年至2015年担任RSI的分析师。2015年至2017年，Venker博士是纽约长老会医院/哥伦比亚大学医学中心的医生，在那里他接受了内科培训，并担任家庭成员质量委员会主席，领导提高效率的运营计划。Venker从2011年到2015年担任Yale-New Haven Hospital临床药剂师。Venker博士还担任Arbutus Biopharma Corporation公司和Immunovant，Inc.公司的董事，这两家公司都是生物制药公司，Venker博士获得了医药博士学位。St.Louis College of Pharmacy的医学博士学位和Yale School of Medicine的医学博士学位。
- Eric Venker has served as Immunovant, Inc.'s Chief Executive Officer since April 2025 and as a member of Immunovant, Inc.'s Board since February 2020. Dr. Venker continues to serve with RSI as President and Immunovant CEO, having previously served as President and Chief Operating Officer of RSI since January 2021, and prior to that, as Chief Operating Officer of RSI since November 2018. Previously, from October 2017 to October 2018, he was Chief of Staff to RSI's Chief Executive Officer, and from 2014 to 2015, an Analyst at RSI. From 2015 to 2017, Dr. Venker was a physician at New York Presbyterian Hospital/Columbia University Medical Center, where he trained in internal medicine. From 2011 to 2015, Dr. Venker was a Clinical Pharmacist at Yale New Haven Hospital. Dr. Venker presently serves on the boards of directors of several of Roivant's private biopharmaceutical companies. Dr. Venker previously served on the boards of Sio Gene Therapies, Inc. and Arbutus Biopharma Corporation. He received his Pharm.D. from St. Louis College of Pharmacy and his M.D. from Yale School of Medicine.
- Richard Pulik
Richard Pulik，自2021年10月起担任Roivant Sciences Ltd.首席财务官。在加入Roivant之前，Pulik先生曾于2019年8月至2021年9月在诺华担任肿瘤学业务发展与许可和投资组合管理全球主管，并担任诺华创新管理委员会和诺华肿瘤学领导团队成员。Pulik先生于2012年加入诺华，担任总部位于瑞士巴塞尔的并购高级总监，负责制定战略和执行影响诺华的交易。2015年，普利克被任命为诺华副总裁兼北美投资者关系主管。在诺华担任这些职务之前，Pulik先生曾在美银美林、摩立特集团和瑞银投资银行工作，专注于医疗保健领域的并购和战略。普利克在沃顿商学院获得金融学士学位，在宾夕法尼亚大学获得经济和国际关系学士学位。
Richard Pulik has served as Chief Financial Officer since October 2021. Prior to joining Roivant, Mr. Pulik was the Global Head of Business Development & Licensing and Portfolio Management, Oncology at Novartis and a member of Novartis's Innovation Management Board and the Novartis Oncology Leadership Team, from August 2019 to September 2021. Mr. Pulik joined Novartis in 2012 as a Senior Director, Mergers & Acquisitions based in Basel, Switzerland working on the strategy and execution of the deals that shaped Novartis. In 2015, Mr. Pulik was appointed as Vice President, Head of North America Investor Relations for Novartis. Prior to these roles at Novartis, Mr. Pulik worked at Bank of America Merrill Lynch, Monitor Group and UBS Investment Bank, focusing on mergers and acquisitions and strategy in the healthcare sector. Mr. Pulik received a B.S. in Finance from The Wharton School and a B.A. in Economics and International Relations at the University of Pennsylvania.- Richard Pulik，自2021年10月起担任Roivant Sciences Ltd.首席财务官。在加入Roivant之前，Pulik先生曾于2019年8月至2021年9月在诺华担任肿瘤学业务发展与许可和投资组合管理全球主管，并担任诺华创新管理委员会和诺华肿瘤学领导团队成员。Pulik先生于2012年加入诺华，担任总部位于瑞士巴塞尔的并购高级总监，负责制定战略和执行影响诺华的交易。2015年，普利克被任命为诺华副总裁兼北美投资者关系主管。在诺华担任这些职务之前，Pulik先生曾在美银美林、摩立特集团和瑞银投资银行工作，专注于医疗保健领域的并购和战略。普利克在沃顿商学院获得金融学士学位，在宾夕法尼亚大学获得经济和国际关系学士学位。
- Richard Pulik has served as Chief Financial Officer since October 2021. Prior to joining Roivant, Mr. Pulik was the Global Head of Business Development & Licensing and Portfolio Management, Oncology at Novartis and a member of Novartis's Innovation Management Board and the Novartis Oncology Leadership Team, from August 2019 to September 2021. Mr. Pulik joined Novartis in 2012 as a Senior Director, Mergers & Acquisitions based in Basel, Switzerland working on the strategy and execution of the deals that shaped Novartis. In 2015, Mr. Pulik was appointed as Vice President, Head of North America Investor Relations for Novartis. Prior to these roles at Novartis, Mr. Pulik worked at Bank of America Merrill Lynch, Monitor Group and UBS Investment Bank, focusing on mergers and acquisitions and strategy in the healthcare sector. Mr. Pulik received a B.S. in Finance from The Wharton School and a B.A. in Economics and International Relations at the University of Pennsylvania.
- Jennifer Humes
詹妮弗·休姆斯曾是摩根大通的全球投资银行财务总监，在那里她领导了一个全球团队，负责全球银行业务的会计、报告和财务报告内部控制。在此之前，Humes女士在摩根大通和花旗银行从事会计政策工作，在那里她支持各种批发和消费业务。她在普华永道和德勤开始了她的公共会计职业生涯，在明尼阿波利斯、圣地亚哥、伦敦和纽约从事审计和技术会计咨询业务。Humes女士获得了圣托马斯大学会计学学士学位。
Jennifer Humes has served as Chief Accounting Officer since February 2025, leading Roivant's accounting and financial operations and related internal controls functions. Prior to joining Roivant, Ms. Humes was the Global Investment Banking Controller at JPMorganChase, where she led a global team responsible for the accounting, reporting and internal controls over financial reporting for the global banking business. Prior to that, Ms. Humes was in accounting policy at JPMorganChase and at Citibank, where she supported various wholesale and consumer businesses. She began her career in public accounting at PwC and Deloitte, spending time in both the auditing and technical accounting advisory practices in Minneapolis, San Diego, London and New York. Ms. Humes received a B.A. in Accounting from The University of St. Thomas.- 詹妮弗·休姆斯曾是摩根大通的全球投资银行财务总监，在那里她领导了一个全球团队，负责全球银行业务的会计、报告和财务报告内部控制。在此之前，Humes女士在摩根大通和花旗银行从事会计政策工作，在那里她支持各种批发和消费业务。她在普华永道和德勤开始了她的公共会计职业生涯，在明尼阿波利斯、圣地亚哥、伦敦和纽约从事审计和技术会计咨询业务。Humes女士获得了圣托马斯大学会计学学士学位。
- Jennifer Humes has served as Chief Accounting Officer since February 2025, leading Roivant's accounting and financial operations and related internal controls functions. Prior to joining Roivant, Ms. Humes was the Global Investment Banking Controller at JPMorganChase, where she led a global team responsible for the accounting, reporting and internal controls over financial reporting for the global banking business. Prior to that, Ms. Humes was in accounting policy at JPMorganChase and at Citibank, where she supported various wholesale and consumer businesses. She began her career in public accounting at PwC and Deloitte, spending time in both the auditing and technical accounting advisory practices in Minneapolis, San Diego, London and New York. Ms. Humes received a B.A. in Accounting from The University of St. Thomas.